Oncology, cancer prevention, tumor biology, and immunotherapy relevant to longevity
631 articles
A Nature study reveals neurons physically transfer mitochondria to breast cancer cells via tunneling nanotubes, boosting metastatic potential.
A high-MAPK, low-WNT tumor cell state drives CRC metastasis, and blocking mutant KRAS suppresses it in mice.
A short pre-surgery course of pembrolizumab left zero relapses in colorectal cancer patients after 33 months — reshaping treatment strategy.
A mouse study finds that senolytic drugs cannot prevent chemotherapy-driven bone loss, challenging a leading hypothesis about its cause.
A comprehensive review reveals how iron-driven cell death can be exploited to treat ATC, one of the most lethal human cancers.
A phase 1/2 trial combined mocetinostat and durvalumab in 83 patients with advanced solid tumors and NSCLC.
A completed Phase II trial tests whether combining two checkpoint inhibitors can safely and effectively treat melanoma that has spread to the brain.
A cancer patient on nivolumab developed Eikenella corrodens bacteremia after CNS infection, revealing how immune checkpoint therapy may enable dangerous microbial dissemination.
The FDA expanded accelerated approval for zongertinib in HER2-mutant NSCLC, marking a targeted therapy milestone for a hard-to-treat mutation.
Tissue stiffness triggers a chain reaction — recruiting macrophages that generate DNA-damaging lipid byproducts — linking fibrosis directly to cancer initiation.
Tumor cells in intrahepatic cholangiocarcinoma hijack IL-6 signaling to fuel growth — creating a targetable metabolic vulnerability.
Phase I trial of Temab-A reports 15.6% response rate and 74.6% disease control in heavily pretreated metastatic colorectal cancer patients.
